Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||New drugs for multiple myeloma|
|Citation:||Australian Prescriber, 2009; 32(4):95-98|
|Michael Osborn, Noemi Horvath and Luen Bik To|
|Abstract:||Multiple myeloma is a plasma cell neoplasm that is currently incurable. Older patients are managed with melphalan and prednisolone. Younger patients have induction chemotherapy followed by high-dose melphalan and autologous stem cell transplantation. Recent insights into the biological basis of myeloma have resulted in several new drugs becoming available. Thalidomide, bortezomib and lenalidomide have each improved the response to therapy, but they are expensive. Future challenges include optimising the sequence of these drugs, refining their combination with standard drugs and high-dose therapy, and identifying the subgroups of patients most likely to benefit from them.|
|Keywords:||Bortezomib; lenalidomide; thalidomide; transplantation|
|Appears in Collections:||Pathology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.